Autolus Therapeutics plc

NASDAQ:AUTL

Biotechnology

Healthcare
$1.06 +0.33%

+$0.01 today

Market cap
$282.13M
Beta
2.01
P/E (TTM)
-1.4
EPS (TTM)
-$1.09
52W Low $1.18High $2.70

Volume 2.56M

Average 1.60M

AUTL Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Autolus Therapeutics plcNASDAQ: AUTL

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 6.3%

Gross margin was 6.3% in Q1 FY2026, up 106.1 pp from a year earlier. On a trailing-twelve-month basis it was -11.2%, up 1636.4 pp year over year. Over 3 fiscal years it narrowed by 127.8 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
6.3%+10.6 pp QoQ
Last fiscal yearDec 2025
-27.8%+1265.6 pp YoY
LTMMar 2026
-11.2%+1636.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+106.1 pp——
1 year+1265.6 pp——
3 years-127.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
-27.8%
Year-over-year change
+1265.6pp

Gross Margin vs competitors

How AUTL compares with its peers on the latest reported figures

  • AUTL's LTM Mar 2026 gross margin of -11.2% is the 7th highest of the 9 companies compared; the peer median is 82.3%.
  • Its year-over-year change of +1636.4 pp is the highest of 9, against a peer median of -1.3 pp.
  • Over three fiscal years its change of -127.8 pp compares with a peer median of -7.2 pp.
AUTL Competitors Peer median
Gross Margin for AUTL and competitors
Company Period LTM level YoY 3-year change
DTILPrecision BioSciences, Inc.LTM Mar 202697.0% -3.0 pp-8.0 pp
ATRAAtara Biotherapeutics, Inc.LTM Mar 202696.1% +15.9 pp+407.1 pp
IPSCCentury Therapeutics, Inc.FY202588.0% -12.0 pp-12.0 pp
CRBUCaribou Biosciences, Inc.LTM Mar 202682.6% +610.6 pp-6.4 pp
CLLSCellectis S.A.LTM Mar 202681.9% +0.5 pp+30.8 pp
LEGNLegend Biotech CorporationLTM Sep 202657.0% -3.6 pp+16.2 pp
AUTLAutolus Therapeutics plcLTM Mar 2026-11.2% +1636.4 pp-127.8 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-415.8% +126.5 pp-179.8 pp
LYELLyell Immunopharma, Inc.LTM Mar 2026-7422.6% -7522.6 pp-32052.8 pp
ALLOAllogene Therapeutics, Inc.FY2025— ——
Peer median (excluding AUTL) 82.3%-1.3 pp-7.2 pp

Competitors are the stored peer set for AUTL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.51M6.19M1.7M10.12M75.56M
Cost of Revenue000141.02M96.59M
Gross Profit1.51M6.19M1.7M(130.9M)(21.03M)
Gross Margin100.0%100.0%100.0%-1293.5%-27.8%
Research & Development110.84M117.35M130.48M158.14M128.59M
Selling, General & Admin31.87M31.9M46.75M0131.82M
Operating Expenses141.88M149.09M181.4M110.53M260.41M
Depreciation & Amortization8.46M7.42M6.57M7.72M9.84M
EBITDA(132.48M)(132.24M)(156.77M)(233.07M)(250.26M)
EBITDA Margin-8790.6%-2135.0%-9232.6%-2303.1%-331.2%
Operating Income(140.37M)(142.89M)(179.7M)(241.43M)(281.44M)
Operating Margin-9314.8%-2307.0%-10583.1%-2385.6%-372.4%
Interest Income262K1.71M13.51M32.36M19.02M
Interest Expense1.11M8.91M45.07M9.29M36.76M
Other Income / Expenses(1.66M)(5.67M)(28.7M)22.29M(15.41M)
Income Before Tax(142.04M)(148.57M)(208.4M)(219.13M)(296.85M)
Pre-Tax Margin-9425.2%-2398.6%-12273.4%-2165.4%-392.8%
Income Tax Expense58K272K(19K)1.53M(8.65M)
Net Income(142.1M)(148.84M)(208.38M)(220.66M)(288.2M)
Net Margin-9429.1%-2403.0%-12272.3%-2180.5%-381.4%
EPS (Basic)(1.97)(1.57)(1.20)(0.87)(1.08)
EPS (Diluted)(1.97)(1.57)(1.20)(0.87)(1.08)
Weighted Avg Shares72.08M94.99M173.94M255.16M266.14M
Weighted Avg Shares (Diluted)72.08M94.99M173.94M255.16M266.14M

Autolus Therapeutics plc

NASDAQ:AUTL

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.